Novo Nordisk on Tuesday struck its second licensing deal since receiving a poor reception from investors after presenting its long-term strategy.
Related stories
A Republican midterm defeat will not be an earthquake
Morgan Stanley’s Mike Wilson says an S&P 500 correction may be exactly what the market needs
US-Iran war adds €100bn to EU’s fuel bill
Two stock picks from a money manager who expects small caps to roar in 2027
Global trade weathers Iran, Ukraine and Trump's tariffs
Anthropic ‘warns of existential AI risks to humanity’ in IPO document